Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Pharma

Specialty drugs represent an opportunity to better serve patients, but also pose risks.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Actuarial, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Q&A with the Academy of Nutrition and Dietetics on malnutrition's greatest challenges and opportunities

What if your doctor handed out grocery lists, not a grocery list of pills to take?

Chief Science Officer, Academy of Nutrition and Dietetics
Principal, Oliver Wyman

Physicians are best positioned to curtail the $265 billion wasted annually on unneeded care.

Global Head, Health Services, Oliver Wyman
Professor of Surgery and Health Policy, Johns Hopkins Medicine
Principal, Health & Life Sciences, Oliver Wyman

Those challengers who address critical patient needs beyond traditional treatment will become a force to be reckoned with.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

As one of the fastest-rising categories of healthcare costs, pharmaceuticals need to develop a metric that explains pricing.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe